Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352859 · ClinicalTrials.gov registry record · Phase 4
Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib
A Phase 4 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT00352859: Clinical Trial Phase 4 study, sponsored by Bayer.
NCT00352859 is a Phase 4 study that was terminated before completion, run by Bayer. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00352859, a Phase 4 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to see if taking interferon or gemcitabine along with sorafenib will stop the advanced renal cell cancer from becoming worse in some people. To do this, sorafenib along with gemcitabine or interferon will be compared to treatment with gemcitabine or interferon alone. More safety information on sorafenib will be also collected. About 260 patients with progressed renal cell cancer will be in this study.
Interventions
- DRUG Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon
- DRUG Gemcitabine or Interferon (only)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2006-08 |
| Est. Completion | 2006-11 |
| Phase | Phase 4 |
Why NCT00352859 stopped before completion
NCT00352859 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon is the first listed.
NCT00352859 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00352859 about?
NCT00352859 is a clinical study titled "Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib". The purpose of this study is to see if taking interferon or gemcitabine along with sorafenib will stop the advanced renal cell cancer from becoming worse in some people. To do this, sorafenib along with gemcitabine or interferon will be compared to treatment with gemcitabine or interferon alone. Mor...
What is the current status of trial NCT00352859?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2006-08. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00352859?
The interventions under investigation include: Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon (DRUG), Gemcitabine or Interferon (only) (DRUG).
Who is sponsoring clinical trial NCT00352859?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00352859's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia